NewEdge Advisors’s Entera Bio ENTX Stock Holding History

NewEdge Advisors’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9,000	Closed	-$17.1K	–	4137
2025 Q2	$17.1K	Hold	9,000	–	–	﹤0.01%	3005
2025 Q1	$15.3K	Hold	9,000	–	–	﹤0.01%	2951
2024 Q4	$19.1K	Hold	9,000	–	–	﹤0.01%	2821
2024 Q3	$17.1K	Hold	9,000	–	–	﹤0.01%	2762
2024 Q2	$16.6K	Buy	+9,000	New	+$19.7K	﹤0.01%	2684

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SEIA

Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return

NewEdge Advisors's ENTX Position: Q3 2025 in Review

NewEdge Advisors sold out of Entera Bio (ENTX) in Q3 2025, closing a stake of 9,000 shares — an estimated $17.1K sold.

NewEdge Advisors first reported a position in ENTX in Q2 2024 and held it in 5 quarters. The position peaked at $19.1K in Q4 2024. 22 funds tracked by Wall St. Rank hold ENTX as of Q3 2025.

NewEdge Advisors reported no remaining Entera Bio position as of Q3 2025 after selling out during the quarter.
NewEdge Advisors sold 9,000 Entera Bio shares in Q3 2025, an estimated $17.1K.
NewEdge Advisors first reported a position in Entera Bio in Q2 2024 and held it in 5 quarters.
NewEdge Advisors's Entera Bio position peaked at $19.1K in Q4 2024.
22 funds tracked by Wall St. Rank held Entera Bio as of Q3 2025.

Based on NewEdge Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.